Barclays Reiterates Overweight Rating on BridgeBio Pharma (BBIO) amid tafamidis IP trial update
Tweet Send to a Friend
Barclays analyst Eliana Merle reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "On ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
